NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
Clinical Trials
70 trialsNCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT07086651 2025-12-08
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT02677896 2025-10-24
ARCHES
Astellas Pharma Inc
Phase 3 Completed
NCT03939689 2025-10-14
ARROW
Progenics Pharmaceuticals, Inc.
Phase 2 Completed
NCT04934722 2025-10-01
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02007512 2025-09-02
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT05202301 2025-08-11
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed
NCT06013475 2025-06-12
DEAR-EXT
Bayer
Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT03641560 2025-04-08
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Phase 4 Completed
NCT02091960 2025-04-04
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01889238 2024-12-13
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Pfizer
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT02918968 2024-12-09
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT01534052 2024-12-06
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Astellas Pharma Inc
Phase 2 Completed
NCT01977651 2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4 Completed
NCT02116582 2024-12-06
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT02799745 2024-12-06
ENACT
Astellas Pharma Inc
Phase 2 Completed
NCT02124668 2024-11-21
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Phase 2 Completed
NCT02669771 2024-11-21
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Astellas Pharma Inc
Completed
NCT03328364 2024-11-21
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Astellas Pharma Inc
Completed
NCT04094519 2024-11-20
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT03776968 2024-10-23
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT02495974 2024-10-21
PREMISE
Astellas Pharma Inc
Completed
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT03016312 2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3 Completed
NCT05362149 2024-03-20
DEAR
Bayer
Completed
NCT02987543 2023-10-06
Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca
Phase 3 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT03569280 2023-07-18
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Kangpu Biopharmaceuticals, Ltd.
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT03437941 2023-05-06
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Corcept Therapeutics
Phase 1/2 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed